Compare Atmos Energy Corporation (ATO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Incyte Corporation — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.59B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Atmos Energy Corporation is the larger of the two by market cap, and Atmos Energy Corporation pays a 2.36% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ATO | INCY | |
|---|---|---|
Market Cap | $28.59B | $24.54B |
Sector | Utilities | Health |
52-Week High | $192.25 | $129.93 |
52-Week Low | $162.44 | $81.61 |
Enterprise Value | $38.40B | $20.04B |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $169.58, up 0.99% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q3 2026 earnings of $1.43 per share, beating estimates, and reaffirmed fiscal 2026 guidance. Revenue grew to $4.7 billion in 2025, with a net income margin of 28.5%, while the balance sheet shows $25.19 billion in total assets and manageable leverage.
The outlook is supported by consistent dividend payments and analyst consensus pointing to upside with a $190.57 price target. Key risks include high capital expenditure trends and interest rate sensitivity, but the utility's defensive profile and earnings momentum provide a stable investment case for income-focused shareholders.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
